Visterra-Serum Combine Forces For Dengue Therapy
This article was originally published in Scrip
Executive Summary
US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.